Microdosing

Heroic Dose Event Explores Promise of Psychedelic Medicine for Veterans, Military & Servicemen and Women

Thursday, April 8, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .
  • The Heroic Dose will commence on 22nd April at 8:45 am EST.
  • This one-day virtual conference explores the use of psychedelic therapies for military veterans and first responders in an effort to combat the alarming rates of PTSD, substance abuse and suicide in this valuable yet underserved demographic.
  • This conference will feature some of the finest Navy SEAL and national security professionals, veterans and other servicemen and women, along with knowledgeable experts in psychedelic therapy, researchers, clinicians, companies, advocates.

March Psychedelic Capital Investigates Ethical IP and Financial Instruments

Tuesday, March 30, 2021 - 1:30pm

Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital .
  • (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1), Mind Cure Health Inc (CSE: MCUR), NanoPsy, ATMA Journey Centres , Ethical IP and Financial Instruments panels are moderated by Zuber Lawler.
  • Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.
  • Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.

Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord

Wednesday, March 24, 2021 - 12:00pm

Psygen consists of a team of industry and business experts with over 25 years of direct experience manufacturing psychedelics.

Key Points: 
  • Psygen consists of a team of industry and business experts with over 25 years of direct experience manufacturing psychedelics.
  • The intention of this program is to obtain a market authorization for both a microdose LSD product and a macrodose LSD product.
  • Larose Ventures, SpinCo and Psygen will provide further details in respect of the Transaction in due course by way of press release.
  • Larose Ventures, SpinCo and Psygen assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders

Tuesday, March 16, 2021 - 12:45pm

Utilizing CUREs patented oral film platform CUREfilm for precision dosing, the company intends to optimize the absorption and metabolism of psychedelic actives targeting clinical efficacy of both macrodosing and microdosing treatment regimens.

Key Points: 
  • Utilizing CUREs patented oral film platform CUREfilm for precision dosing, the company intends to optimize the absorption and metabolism of psychedelic actives targeting clinical efficacy of both macrodosing and microdosing treatment regimens.
  • CURE will use its DEA Schedule 1 license and cGMP-certified and FDA-registered facility providing a United States footprint for anticipated commercialization.
  • Our specialty pharmaceutical pipeline is robust, protected by our IP and differentiated relative to others developing psychedelics, said Rob Davidson, CEO of CURE.
  • Advancing these psychedelic product development programs helps ensure our end-goal of targeting those patients who would have otherwise been left without an important treatment option.

Microdose Announces the Launch of Accredited Course Series "The Science of Psychedelics: Training for Medical Professionals"

Wednesday, March 10, 2021 - 1:30pm

Microdose to launch The Science of Psychedelics: Training for Medical Professionals

Key Points: 
  • Microdose to launch The Science of Psychedelics: Training for Medical Professionals
    TORONTO, March 10, 2021 /PRNewswire/ --Microdose is pleased to announce The Science of Psychedelics: Training for Medical Professionals , an online, accredited course series for physicians, psychologists, social workers, mental health counsellors, pharmacists, and other medical professionals.
  • "After teaching internationally, I am thrilled to now be able to offer my sought-after psychedelic training online.
  • I want practitioners everywhere to have the information they need to help people in the safest, most meaningful way possible."
  • To promote the launch of The Science of Psychedelics, Microdose is currently offering 15% off any version of the course for the next 7 days.

Red Light Holland's iMicro Digital Care App Launches Virtual Telecounseling with a Membership Program Led by Certified Therapist and Microdosing Expert

Wednesday, March 3, 2021 - 1:52pm

The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms.

Key Points: 
  • The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms.
  • Online support will be offered to adults exploring microdosing with iMicrodose packs powered by Red Light Holland in the Netherlands.
  • Members will be able to approve and share their iMicro Digital Care app data and connect with Red Light Holland's certified therapist and microdosing expert, Jeff Hamburg, who will provide live virtual telecounseling.
  • "Red Light Holland is extremely proud to introduce virtual telecounseling, the use of digital information and communication technologies to help support the microdosing community.

Eyenovia Announces FDA Acceptance of the MydCombi NDA

Tuesday, March 2, 2021 - 12:30pm

If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.

Key Points: 
  • If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
  • If approved, we believe MydCombi would provide patients with one of the biggest advances in clinical mydriasis in the last few decades.
  • MydCombi was developed with the goal of providing a touchless fixed combination microdose formulation to improve the patients clinical experience.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Monday, February 1, 2021 - 12:30pm

Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration.

Key Points: 
  • Unlike other companies recently researching psychedelic drugs, Algernon will be focusing on a sub-hallucinogenic, or microdose of DMT provided by continuous intravenous administration.
  • Named the Spirit Molecule by Dr. Rick Strassman, an American clinical associate professor of psychiatry and DMT research pioneer, DMT has been shown to induce neuroplasticity in a number of key preclinical studies.
  • The Company has also retained Novotech to conduct a feasibility study for Algernon to conduct all or part of its DMT stroke clinical research program in Australia.
  • Algernon is also exploring conducting its DMT clinical research program in other countries as well.

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

Tuesday, January 12, 2021 - 12:30pm

The study will provide an additional research pathway for MindMed's psychedelic Microdosing Division and will immediately integrate with MindMed's plans in digital therapeutics through its newly formed Albert unit for digital medicine.

Key Points: 
  • The study will provide an additional research pathway for MindMed's psychedelic Microdosing Division and will immediately integrate with MindMed's plans in digital therapeutics through its newly formed Albert unit for digital medicine.
  • MindMed is integrating innovative digital tracking devices and software into the study to better assess LSD's effects on various digital clinical markers on the human body.
  • In addition to this study, MindMed's Microdosing Division under the leadership of Dr. Halperin Wernli is undertaking a commercial Phase 2a Adult ADHD clinical trial evaluating microdoses of LSD.
  • The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

Tuesday, January 5, 2021 - 12:30pm

In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.

Key Points: 
  • In this study people who already have an established practice of microdosing will come to the lab to complete a cutting-edge battery of measures.
  • Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition, said Dr. Polito.
  • This study will further shed light on currently ambiguous effects of microdosing, said Josh Bartch, CEO and Co-Founder of Mydecine.
  • Mydecine Innovations Group is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.